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Amyloidosis is a group of conditions that involve
the deposition of amyloid proteins in various
tissues. It is generally classified as either systemic
or cutaneous. Primary localized cutaneous nodular
amyloidosis (PLCNA) is the rarest form of cutaneous
amyloidosis with the amyloid depositing in the
dermis, subcutis, and blood vessel walls.
Management of PLCNA is challenging, as there
is no consistently effective treatment, and local
recurrence is common. Management options include
surgical excision, dermabrasion, electrodessication
and curettage, cryotherapy, carbon dioxide laser,
pulse dye laser, intralesional steroids, and cyclo-
phosphamide. We report a case of PLCNA in which
intralesional methotrexate has been used with good
effect.Fig 1. PLCNApretreatmentwith intralesionalmethotrexate.CASE REPORT
A 77-year-old man was referred to a dermatologist
for management of large firm nodules and plaques
on his lower face and neck. The lesions had
been present for approximately 2 months before
dermatology review. No treatments were trialled
before dermatology referral (Fig 1). A biopsy of a
lesion on the patient’s chin found nodular deposits
of eosinophilic hyalinized globular material for the
whole thickness of the dermis, patchy plasmacytic
chronic inflammatory infiltrate in adjacent stroma,
and normal epidermis. Stains with Periodic
acideSchiff crystal violet and Congo red were
strongly positive, and polarized light of Congo
redestained sections showed characteristic yellow-
green birefringence. Histologic findings were classicWestmead Hospitala; Concord Repatriation General Hospi-
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m.for PLCNA (Fig 2). Similar lesions were present on
the patient’s neck but were not biopsied. Routine
blood test results showed abnormal blood protein
levels, and subsequent serum electrophoresis
confirmed monoclonal gammopathy of unknown
significance. The potential for secondary systemic
amyloidosis was then investigated with serum and
urine protein electrophoresis, echocardiogram and
bone marrow biopsy. In the absence of investigation
findings for secondary systemic amyloidosis, the
condition was classified as primary cutaneousJAAD Case Reports 2016;2:373-6.
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Fig 2. A-E, Histology findings.
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Initially, the patient was given betamethasone
dipropionate 0.1% twice daily for the nodules on the
face and neck. After 4 weeks of topical corticosteroid
treatment, there was no improvement in the patient’s
condition. Two intralesional corticosteroid injections
(triamcinolone, 40 mg/mL) were administered to
the nodular lesions over a 2-month period without
any improvement in conjunction with topical
betamethasone dipropionate 0.1% twice daily on a
second weekly basis. Intralesional methotrexate in-
jections were then started for lesions on cheeks,
upper lip, and chin. Initially, only 2 nodules on the
cheeks were treated, but eventually all nodules on
both cheeks, upper lip, and chin region were
injected. Excision or pulse dye laser therapy is beingconsidered for lesions on the neck, as they are less
conspicuous.
The initial dose of methotrexate was 12.5 mg,
which was titrated up to 25 mg then 40 mg then
50 mg. The period between treatments ranged
between 2 and 4 weeks in the early stages to
determine whether the patient would tolerate
methotrexate. Upon ascertaining tolerance, 50-mg
injections were administered on a weekly basis
over a 6-month period without folic acid. This
regimen resulted in a significant reduction in size
of the treated lesions, and they remain stable (Fig 3).
However, untreated nodules have recently started
growing, and new lesions are developing in un-
treated areas on the back of the patient’s neck and
eyebrows. Weekly to fortnightly monitoring of full
blood count, electrolytes, urea & creatinine, and liver
Fig 3. A and B, PLCNA posttreatment with intralesional methotrexate.
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malities resulting in cessation of injections.
DISCUSSION
Treatment of PLCNA is challenging, and various
modalities are used in its management. A 585-nm
pulsed dye laser has been used with few
complications, but multiple treatments are required
to achieve the desired clinical effect.1 Intralesional
corticosteroids are ineffective and may actually accel-
erate amyloid deposition.2 Dermabrasion is effective
in nodular amyloidosis,3 but the limitation is that the
amyloid is often deposited more deeply in the skin
with PLCNA. Carbon dioxide laser has been usedwith
good cosmetic results, but residual amyloid may
persist, and there are concerns about tissue friability
along with achieving hemostasis.4 Cryotherapy is
unsuccessful in the treatment of PLCNA, but curettage
and cautery produces an acceptable cosmetic result.5
Surgical excision with or without split skin graft yields
satisfactory cosmetic results.6
Tong et al7 presented a case of PLCNA in which
the patient was treated with multiple immunosup-
pressive agents with little effect on the number or
size of lesions. Systemic cyclophosphamide and
prednisolone were used in combination, which
resulted in healing of the patient’s ulcers,
stabilization of existing nodules, and no develop-
ment of new nodules.7We contend that the delivery of an extremely
high concentration of intralesional methotrexate
produces a much increased localized antimitotic
effect. But it remains unclear whether methotrexate
administered intralesionally is superior to systemic
treatment. Tong et al7 used systemic methotrexate,
25 mg weekly for 3 months, without success, and
their patient subsequently developed abnormal
LFTs.2 Our patient received intralesional metho-
trexate with a dose up to 50 mg weekly for 6 months
with the development of minor LFT derangement at
that time. A direct comparison cannot be made
between these patients given the dosage discrep-
ancy. But we believe that intralesional methotrexate
yields high localized tissue concentrations that
cannot be achieved with systemic dosing because
of potential toxicity. The systemic methotrexate
levels in our patient were inadequate to produce
shrinkage of distant untreated nodules. But the
clinical improvement seen in our patient denotes a
role for the use of intralesional methotrexate as a
treatment option in patients who have localized
lesions and are poor candidates for surgery or
invasive procedures or patients who do not wish to
risk potential postsurgical scarring. The only dis-
claimers are that it is too early to determine if there
will be recurrence in treated areas and whether
systemic amyloidosis will develop. Strict ongoing
monitoring is in place with respect to these issues
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clonal gammopathy of unknown significance status.
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